By Adriano Marchese
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices.
The pharmaceutical company said it has launched 7.5 and 10 milligram single dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram as well as 10 and 12.5 milligram vials.
The company has also reduced the price through its Self Pay Journey program. The program reduces the price of the 7.5 mg and 10 mg doses to $499 per month from $599 and $699, respectively, at first fill and refills that occur within 45 days of prior delivery.
Eli Lilly's new price points and offerings are only through its proprietary LillyDirect Self Pay Pharmacy Solutions which the company said "enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance."
Zepbound, a dual receptor agonist obesity medication, reduces appetite and how much the recipient can eat, supporting other weight loss efforts such as reduced calorie diets and physical exercise.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram vials. "Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points," at 7:21 a.m. incorrectly said Zepbound also comes in 10 and 12.5 milligram vials.
(END) Dow Jones Newswires
February 25, 2025 09:02 ET (14:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.